Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
As researchers and clinicians are beginning to understand that wet age-related macular degeneration (AMD) is more than simply a vascular disease that includes angiogenic, vascular and inflammatory components, they are exploring new agents with different mechanisms of action addressing multiple targets in this complex pathophysiology. Some of them are already available in human trials or even approved vascular epithelial growth factor (VEGF) blockers such as Macugen, Lucentis, Avastin, VEGF Trap-Eye and Cand5; VEGF receptor blockers such as TG100801, vatalanib, pazopanib, Sirna-027 and a vaccine approach; inflammation inhibitors and immunosuppressants such as Retaane, Kenalog, ARC1905, POT-4, OT-551. The last group is mixed, containing agents such as Zybrestat, AdPEGF, Sirolimus, JSM6427, ATG003, E10030. This article reviews these currently emerging agents and briefly discusses the next step for the treatment of wet AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“716 patients with minimal classic or occult CNV secondary to AMD were treated with a 0.3- or 0.5-mg dose of Lucentis IVT or sham injections monthly. The results demonstrated that 94.5 and 94.6p of Lucentis-treated patients lost fewer than 15 letters (0.3 and 0.5 mg, respectively), compared with 62p of sham-treated pat…”
ResultInfluentialPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“Macugen (Pegaptanib Sodium 0.3 mg; Eyetech/Pfizer) Pegaptanib [”
InfluentialRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Drusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Cited by
Biodegradable Implants for Sustained Drug Release in the Eye
Lee, S. S., Hughes, P., Ross, A. D., & Robinson, M. R. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0159-x · Cited by 289
Parallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280
“…Iemediated C3B proteolysis, inhibition of C3 and/or C5 convertase activities, inhibition of membrane attack complex assembly by C5b-9, and reestablishment of the normal alternative complement pathway through augmentation with the protective CFH protein (Ni and Hui, 2009; Ricklin and Lambris, 2007).”
BackgroundEhrnthaller, C., Ignatius, A., Gebhard, F., & Huber-Lang, M. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00149 · Cited by 226
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
Patel, S., Garapati, C., Chowdhury, P., Gupta, H., Nesamony, J., Nauli, S., & Boddu, S. H. S. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0152 · Cited by 48
Metadata
- Authors
- Ni, Z., & Hui, P.
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 223
- Issue
- 6
- Pages
- 401-410
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W1972231974
- Cited by
- 67
- References
- 5
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1159/000228926
- The paper
- Ni, Z., & Hui, P. (2009). Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration. Ophthalmologica. https://doi.org/10.1159/000228926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.